BackgroundA decline in driving skills is well documented in people with dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
33,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
BackgroundA decline in driving skills is well documented in people with dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The combined advances of a new, protease-resistant SDF-1 and nanofiber-mediated delivery promoted recruitment of stem cells and improved cardiac function after myocardial infarction. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Twenty-two patients with Parkinson's disease drawn from a community-based study were followed prospectively until their deaths. 2 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
To assess the occurrence and related features of motor vehicle crashes in patients with dementia of the Alzheimer type (DAT) we studied 30 patients who had been followed longitudinally and 20 healthy age-matched control subjects. 2 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
A 59-year-old man developed problems with reading and driving. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia adversely affects driving performance even in its mild stages, although some persons with DAT seem to drive safely for some time after disease onset. 1 key finding →
Participants: 123 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings show an association between low circulating levels of one of the most important components of the human antioxidant system and the presence of frailty. 3 key findings →
Participants: 827 Evidence: low
Full summary, score breakdown and related studies → Original source
EEG findings in 62 patients with senile dementia of alzheimer type (SDA), 22 patients with multi-infarct dementia (MID) and 90 controls of same age and sex were studied. 3 key findings →
Participants: 62 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a major cause of dementia in older adults and is fast becoming a major societal and economic burden due to an increase in life expectancy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our in vivo model of c9FTD/ALS is the first to robustly recapitulate hallmark features derived from both sense and antisense C9orf72 repeat-associated transcripts complete with neurodegeneration and behavioral impairments. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Degeneration of frontal and temporal lobes predisposes to antisocial behaviour. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although automobiles remain the transportation of choice for many older adults, late-life cognitive impairment and dementia often impair the ability to drive safely. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The fornix is a white matter bundle located in the mesial aspect of the cerebral hemispheres, which connects various nodes of a limbic circuitry and is believed to play a key role in cognition and episodic memory recall. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vitamin E was proposed as treatment for Alzheimer's disease many years ago. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aging is a major driving force underlying dementia, such as that caused by Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive decline and late onset Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The present results support that progression to AD dementia is driven by the synergistic rather than a mere additive effect between Aβ and p-tau proteins. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Elevated plasma lipopolysaccharide (LPS), an indicator of microbial translocation from the gut, is a likely cause of systemic immune activation in chronic HIV infection. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
At least nine recent population-based studies of dementia incidence or prevalence have shown a declining age-specific risk in the US, England, The Netherlands, Sweden, and Denmark. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A family is described with familial myoclonic epilepsy associated with mitochondrial myopathy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The kynurenine pathway (KP) is the major metabolic pathway of the essential amino acid tryptophan (TRP). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Formation of biomolecular condensates through liquid-liquid phase separation (LLPS) has emerged as a pervasive principle in cell biology, allowing compartmentalization and spatiotemporal regulation of dynamic cellular processes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research suggests that Alzheimer disease (AD) pathophysiology begins prior to the clinical expression of the disease and that biomarker measures may provide direct evidence of this process. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Prevalence of dementia continues to increase because of the aging population and limited treatment options. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
FUS is a nuclear RNA-binding protein, and its cytoplasmic aggregation is a pathogenic signature of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 33,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 33,380 records, built mostly from automated pulls of Europe PMC (67.7% of the library) and OpenAlex (15.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,047 records (3.1% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated